Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial

Rosa Sciuto, Anna Festa, Sandra Rea, Rosella Pasqualoni, Serenella Bergomi, Germana Petrilli, Carlo L. Maini

Research output: Contribution to journalArticle

Abstract

This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cytostatic effects. Methods: Seventy patients with metastatic hormone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m2 cisplatin, and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the patients were followed up until death to evaluate the outcome variables: grade and duration of pain palliation, onset of new painful sites, changes in bone disease, global survival, serum prostate-specific antigen and alkaline phosphatase changes, and hematologic toxicity. Results: Overall pain relief occurred in 91% of patients in arm A and 63% of patients in arm B (P <0.01), with a median duration of 120 d in arm A and 60 d in arm B (P = 0.002). New painful sites on previously asymptomatic bone metastases appeared in 14% of patients in arm A and in 30% of patients in arm B (P = 0.18). The median survival without new painful sites was 4 mo in arm A and 2 mo in arm B (P = 0.04). Bone disease progression was observed in 27% of patients in arm A and in 64% of patients in arm B (P = 0.01). Median global survival after therapy was 9 mo in arm A and 6 mo in arm B (P = 0.30). Transient and moderate hematologic toxicity, as determined by World Health Organization criteria, was apparent in both arms without significant differences. Conclusion: The addition of a low dose of cisplatin enhances the effect of a standard dose of 89Sr without significant side effects, producing a significant improvement in pain palliation and a cytostatic effect on bone disease.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalJournal of Nuclear Medicine
Volume43
Issue number1
Publication statusPublished - 2002

Fingerprint

Cisplatin
Prostatic Neoplasms
Randomized Controlled Trials
Neoplasm Metastasis
Bone and Bones
Bone Diseases
Pain
Cytostatic Agents
Therapeutics
Survival
Prostate-Specific Antigen
Alkaline Phosphatase
Disease Progression
Placebos
Hormones
Serum

Keywords

  • Cisplatin
  • Pain palliation
  • Prostate cancer
  • Strontium

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer : A randomized clinical trial. / Sciuto, Rosa; Festa, Anna; Rea, Sandra; Pasqualoni, Rosella; Bergomi, Serenella; Petrilli, Germana; Maini, Carlo L.

In: Journal of Nuclear Medicine, Vol. 43, No. 1, 2002, p. 79-86.

Research output: Contribution to journalArticle

Sciuto, R, Festa, A, Rea, S, Pasqualoni, R, Bergomi, S, Petrilli, G & Maini, CL 2002, 'Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial', Journal of Nuclear Medicine, vol. 43, no. 1, pp. 79-86.
Sciuto, Rosa ; Festa, Anna ; Rea, Sandra ; Pasqualoni, Rosella ; Bergomi, Serenella ; Petrilli, Germana ; Maini, Carlo L. / Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer : A randomized clinical trial. In: Journal of Nuclear Medicine. 2002 ; Vol. 43, No. 1. pp. 79-86.
@article{8e43cb69c0554b9d9c5998e590e6aaf7,
title = "Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial",
abstract = "This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cytostatic effects. Methods: Seventy patients with metastatic hormone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m2 cisplatin, and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the patients were followed up until death to evaluate the outcome variables: grade and duration of pain palliation, onset of new painful sites, changes in bone disease, global survival, serum prostate-specific antigen and alkaline phosphatase changes, and hematologic toxicity. Results: Overall pain relief occurred in 91{\%} of patients in arm A and 63{\%} of patients in arm B (P <0.01), with a median duration of 120 d in arm A and 60 d in arm B (P = 0.002). New painful sites on previously asymptomatic bone metastases appeared in 14{\%} of patients in arm A and in 30{\%} of patients in arm B (P = 0.18). The median survival without new painful sites was 4 mo in arm A and 2 mo in arm B (P = 0.04). Bone disease progression was observed in 27{\%} of patients in arm A and in 64{\%} of patients in arm B (P = 0.01). Median global survival after therapy was 9 mo in arm A and 6 mo in arm B (P = 0.30). Transient and moderate hematologic toxicity, as determined by World Health Organization criteria, was apparent in both arms without significant differences. Conclusion: The addition of a low dose of cisplatin enhances the effect of a standard dose of 89Sr without significant side effects, producing a significant improvement in pain palliation and a cytostatic effect on bone disease.",
keywords = "Cisplatin, Pain palliation, Prostate cancer, Strontium",
author = "Rosa Sciuto and Anna Festa and Sandra Rea and Rosella Pasqualoni and Serenella Bergomi and Germana Petrilli and Maini, {Carlo L.}",
year = "2002",
language = "English",
volume = "43",
pages = "79--86",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer

T2 - A randomized clinical trial

AU - Sciuto, Rosa

AU - Festa, Anna

AU - Rea, Sandra

AU - Pasqualoni, Rosella

AU - Bergomi, Serenella

AU - Petrilli, Germana

AU - Maini, Carlo L.

PY - 2002

Y1 - 2002

N2 - This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cytostatic effects. Methods: Seventy patients with metastatic hormone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m2 cisplatin, and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the patients were followed up until death to evaluate the outcome variables: grade and duration of pain palliation, onset of new painful sites, changes in bone disease, global survival, serum prostate-specific antigen and alkaline phosphatase changes, and hematologic toxicity. Results: Overall pain relief occurred in 91% of patients in arm A and 63% of patients in arm B (P <0.01), with a median duration of 120 d in arm A and 60 d in arm B (P = 0.002). New painful sites on previously asymptomatic bone metastases appeared in 14% of patients in arm A and in 30% of patients in arm B (P = 0.18). The median survival without new painful sites was 4 mo in arm A and 2 mo in arm B (P = 0.04). Bone disease progression was observed in 27% of patients in arm A and in 64% of patients in arm B (P = 0.01). Median global survival after therapy was 9 mo in arm A and 6 mo in arm B (P = 0.30). Transient and moderate hematologic toxicity, as determined by World Health Organization criteria, was apparent in both arms without significant differences. Conclusion: The addition of a low dose of cisplatin enhances the effect of a standard dose of 89Sr without significant side effects, producing a significant improvement in pain palliation and a cytostatic effect on bone disease.

AB - This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cytostatic effects. Methods: Seventy patients with metastatic hormone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m2 cisplatin, and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the patients were followed up until death to evaluate the outcome variables: grade and duration of pain palliation, onset of new painful sites, changes in bone disease, global survival, serum prostate-specific antigen and alkaline phosphatase changes, and hematologic toxicity. Results: Overall pain relief occurred in 91% of patients in arm A and 63% of patients in arm B (P <0.01), with a median duration of 120 d in arm A and 60 d in arm B (P = 0.002). New painful sites on previously asymptomatic bone metastases appeared in 14% of patients in arm A and in 30% of patients in arm B (P = 0.18). The median survival without new painful sites was 4 mo in arm A and 2 mo in arm B (P = 0.04). Bone disease progression was observed in 27% of patients in arm A and in 64% of patients in arm B (P = 0.01). Median global survival after therapy was 9 mo in arm A and 6 mo in arm B (P = 0.30). Transient and moderate hematologic toxicity, as determined by World Health Organization criteria, was apparent in both arms without significant differences. Conclusion: The addition of a low dose of cisplatin enhances the effect of a standard dose of 89Sr without significant side effects, producing a significant improvement in pain palliation and a cytostatic effect on bone disease.

KW - Cisplatin

KW - Pain palliation

KW - Prostate cancer

KW - Strontium

UR - http://www.scopus.com/inward/record.url?scp=0036152138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036152138&partnerID=8YFLogxK

M3 - Article

C2 - 11801708

AN - SCOPUS:0036152138

VL - 43

SP - 79

EP - 86

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -